Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease

NCT00790933 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00790933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00790933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
May 22, 2009
Completion date
October 31, 2017
Enrollment
2,243 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, ulcerative colitis